Literature DB >> 15908974

Donor CD31 genotype and its association with acute graft-versus-host disease in HLA identical sibling stem cell transplantation.

R S Goodman1, J Ewing, P C Evans, J Craig, K Poulton, P A Dyer, R E Marcus, C J Taylor.   

Abstract

CD31 gene polymorphisms are implicated in the pathogenesis of graft-versus-host disease (GvHD) following haematopoietic stem cell transplantation (HST). We investigated the influence of CD31 genotype on the incidence of GvHD following HST from an human leukocyte antigen (HLA)-identical sibling donor. Donor and recipient CD31 codons 125, 563 and 670 DNA polymorphisms were determined in 85 cases of HLA identical sibling HST from two transplant centres. A correlation between CD31 genotype and acute GvHD was considered significant if observed in patients from both transplant centres independently. A strong correlation was identified between donor CD31 codon 125 genotype and the incidence of acute GvHD. Acute GvHD grades II-IV occurred in 27 of 46 (59%) recipients with a CD31 codon 125 leucine / valine heterozygous donor compared to nine of 39 (23%) recipients with a CD31 codon 125 homozygous donor (P=0.0019, relative-risk 2.45, 95% confidence interval 1.3-4.5). This correlation was significant in patients from both transplant centres (P=0.015 and P=0.019). We suggest that CD31 genotype may influence the function of donor-derived leukocytes and may be informative when there is a choice of comparable donors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908974     DOI: 10.1038/sj.bmt.1705013

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Association between genetic variants in adhesion molecules and outcomes after hematopoietic cell transplants.

Authors:  B Thyagarajan; S Jackson; S Basu; P Jacobson; M D Gross; D J Weisdorf; M Arora
Journal:  Int J Immunogenet       Date:  2012-05-30       Impact factor: 1.466

2.  CD31 signals confer immune privilege to the vascular endothelium.

Authors:  Kenneth Cheung; Liang Ma; Guosu Wang; David Coe; Riccardo Ferro; Marco Falasca; Christopher D Buckley; Claudio Mauro; Federica M Marelli-Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-21       Impact factor: 11.205

Review 3.  Evaluation of published single nucleotide polymorphisms associated with acute GVHD.

Authors:  Jason W Chien; Xinyi Cindy Zhang; Wenhong Fan; Hongwei Wang; Lue Ping Zhao; Paul J Martin; Barry E Storer; Michael Boeckh; Edus H Warren; John A Hansen
Journal:  Blood       Date:  2012-01-26       Impact factor: 22.113

4.  CD31 exhibits multiple roles in regulating T lymphocyte trafficking in vivo.

Authors:  Liang Ma; Kenneth C P Cheung; Madhav Kishore; Sussan Nourshargh; Claudio Mauro; Federica M Marelli-Berg
Journal:  J Immunol       Date:  2012-09-10       Impact factor: 5.422

Review 5.  NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges.

Authors:  Smita Bhatia; Stella M Davies; K Scott Baker; Michael A Pulsipher; John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-18       Impact factor: 5.742

6.  Extracellular vesicles as potential biomarkers of acute graft-vs-host disease.

Authors:  G Lia; L Brunello; S Bruno; A Carpanetto; P Omedè; M Festuccia; L Tosti; E Maffini; L Giaccone; M Arpinati; G Ciccone; M Boccadoro; A Evangelista; G Camussi; B Bruno
Journal:  Leukemia       Date:  2017-08-30       Impact factor: 11.528

Review 7.  Role of non-HLA gene polymorphisms in graft-versus-host disease.

Authors:  Akiyoshi Takami
Journal:  Int J Hematol       Date:  2013-08-15       Impact factor: 2.490

8.  Primed T cell responses to chemokines are regulated by the immunoglobulin-like molecule CD31.

Authors:  Madhav Kishore; Liang Ma; Georgina Cornish; Sussan Nourshargh; Federica M Marelli-Berg
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.